The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Open accessAbstract
Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, and hence TNBC is managed with conventional therapeutics, often leading to systemic relapse. In terms of histology and transcription profile these cancers have similarities to BRCA-1-linked breast cancers, and it is hypothesized that BRCA1 pathway is non-functional in this type of breast cancer. In this review article, we discuss the different receptors expressed by TNBC as well as the diversity of different signaling pathways targeted by TNBC therapeutics, for example, Notch, Hedgehog, Wnt/b-Catenin as well as TGF-beta signaling pathways. Additionally, many epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors effectively inhibit the TNBCs, but they face challenges of either resistance to drugs or relapse. The resistance of TNBC to conventional therapeutic agents has helped in the advancement of advanced TNBC therapeutic approaches including hyperthermia, photodynamic therapy, as well as nanomedicine-based targeted therapeutics of drugs, miRNA, siRNA, and aptamers, which will also be discussed. Artificial intelligence is another tool that is presented to enhance the diagnosis of TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Hsiao, Y.-C., Yeh, M., Chen, Y., Liu, J., Tang, C., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5700 · Cited by 43
Prognostic Value of MammaPrint ® in Invasive Lobular Breast Cancer
Beumer, I. J., Persoon, M., Witteveen, A. T., Dreezen, C., Chin, S., Sammut, S., Snel, M. H. J., Caldas, C., Linn, S. C., Veer, L. V. ‘., et al. (2016) · Biomarker Insights · doi:10.4137/bmi.s38435 · Cited by 41
Review Immunotargeting of cancer stem cells
Kwiatkowska-Borowczyk, E. P., Gąbka-Buszek, A., Jankowski, J., & Mackiewicz, A. A. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47129 · Cited by 40
‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials
Kilburn, L. S. (2008) · Clinical Oncology · doi:10.1016/j.clon.2007.09.010 · Cited by 37
Zhang, Y., Liu, F., Zhang, C., Ren, M., Kuang, M., Xiao, T., Di, X., Feng, L., Fu, L., & Cheng, S. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.09.014 · Cited by 37
Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
Park, S. R., & Chen, A. P. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.012 · Cited by 31
Sobande, F., Dušek, L., Matějková, A., Rozkoš, T., Laco, J., & Ryška, A. (2015) · PubMed · Cited by 30
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
Huynh, M.-M., Jayanthan, A., Pambid, M. R., Los, G., & Dunn, S. E. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1709824 · Cited by 28
Combining Notch inhibition with current therapies for breast cancer treatment
Brennan, K. R., & Clarke, R. B. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012457437 · Cited by 27
Emerging Trends in the Treatment of Triple-Negative Breast Cancer in Canada: A Survey
Verma, S., Provencher, L., & Dent, R. A. (2011) · Current Oncology · doi:10.3747/co.v18i4.913 · Cited by 26
Brigitte Séroussi, A., Guézennec, G., Lamy, J.-B., Muro, N., Larburu, N., Sekar, B. D., Prebet, C., & Jacques Bouaud, A. (2017) · Ulster University Research Portal (Ulster University) · doi:10.5281/zenodo.1466821 · Cited by 25
Methods for L-ribooligonucleotide sequence determination using LCMS
Turner, J. J., Hoos, J. S., Vonhoff, S., & Klußmann, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr776 · Cited by 19
Artificial Intelligence and the Softer Side of Medicine.
Craft, J. A. (2018) · Europe PMC (PubMed Central) · Cited by 19
Heussler, H., & Suri, M. (2003) · Molecular Pathology · doi:10.1136/mp.56.3.129 · Cited by 16
Chen, C., Yuan, J., Wei, W., Tu, Y., Yao, F., Yang, X., Tian, W., Sun, S., & Li, Y. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s58270 · Cited by 15
Zheng, H., Chen, C., Wu, X., Chen, J., Sun, S., Jin-zhong, S., Wang, M.-W., & Sun, S. (2015) · Tumor Biology · doi:10.1007/s13277-015-4079-6 · Cited by 12
Biosensing Using Nanoelectromechanical Systems
Yeri, A., & Gao, D. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-052-2_9 · Cited by 11
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Rahim, M. A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., et al. (2021) · Cancers · doi:10.3390/cancers13040670 · Cited by 323
Biological Function of Long Non-coding RNA (LncRNA) Xist
Wang, W., Min, L., Qiu, X., Wu, X., Liu, C., Ma, J., Zhang, D., & Zhu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645647 · Cited by 248
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T.
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2020-03-20
- Volume
- 17
- Issue
- 6
- Pages
- 2078
- ISSN
- 1660-4601 (ISSN-L)
- OpenAlex
- W3012440210
- Cited by
- 333
- References
- 217
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.